A systematic review of international/national guidelines for the management of nasopharyngeal carcinoma: Convergence and divergence of recommendations.

CancerSep 12, 2026
Clinical ResearchOncology (Medical)

Qin Liu, Handoko, Ji-Shi Li et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review analyzed 26 clinical practice guidelines for nasopharyngeal carcinoma (NPC) published from January 2000 to November 2025. The study found strong consensus on diagnostic workup and treatment for advanced disease, but significant discrepancies in radiotherapy details and systemic therapy options. The review highlights the need for standardization in NPC management.

Key findings

  • Strong consensus exists for diagnostic workup and staging systems in NPC management.
  • Induction chemotherapy plus concurrent chemoradiotherapy is widely recommended for advanced NPC.
  • Marked disparities were found in radiotherapy details, including target volume delineation and dose specifications.
  • Substantial inconsistencies exist in systemic therapy options across different stage groups.

Why it matters

Understanding the variations in clinical practice guidelines for nasopharyngeal carcinoma is crucial for clinicians to make informed treatment decisions. This review aids in identifying areas of consensus and controversy, which can guide future research and improve patient care.

Source

PubMed · PMID 42726913

Published in Cancer. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.